Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
Akihiko KoshinoMeir SchechterTaha SenPriya VartBrendon L NeuenBruce C NealClare ArnottVlado PerkovicPaul M RidkerKatherine R TuttleMichael K HansenHiddo J Lambers HeerspinkPublished in: Diabetes care (2022)
In patients with type 2 diabetes at high CV risk, baseline IL-6 and its 1-year change were associated with CV and kidney outcomes. The effect of IL-6-lowering therapy on CV, kidney, and safety outcomes remains to be tested.